Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients
Vikas S. Sridhar(University Health Network), Sunita Singh(University Health Network), Daan J. Touw(University Medical Center Groningen), Massimo Nardone(University Health Network), David Z.I. Cherney(University Health Network), Leif E. Lovblom(University of Toronto), Hiddo J.L. Heerspink(University Medical Center Groningen), Hongyan Liu(University of Toronto), Yangqing Deng(University Health Network), Yuliya Lytvyn(University Health Network), Luxcia Kugathasan(University of Toronto), Jacob A. Udell(University Health Network), Jasper Stevens(University Medical Center Groningen), Mai Mohsen(University Health Network), See Kim(University Health Network), Bruce A. Perkins(Sinai Health System), Yarden Aronson(McGill University), Darren A. Yuen(St. Michael's Hospital)
Cited by 6
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
|The Lancet|2012|1.4k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990